Share Price and Basic Stock Data
Last Updated: December 8, 2025, 11:42 pm
| PEG Ratio | 1.17 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gillanders Arbuthnot & Company Ltd, operating in the tea and coffee plantation industry, has shown a mixed performance in its revenue trajectory. For the fiscal year ending March 2025, the company recorded sales of ₹443 Cr, a slight recovery from ₹363 Cr in March 2024. However, this is a notable decline from the ₹449 Cr reported in March 2023. The quarterly sales figures illustrate volatility, with the latest quarter showing ₹105.42 Cr in September 2023, after a dip to ₹77.42 Cr in March 2023. This inconsistency raises questions about operational stability, especially in a sector typically known for steady demand. The company’s market capitalization stands at ₹231 Cr, reflecting a price-to-earnings ratio of 16.9, which appears reasonable given the current profitability metrics. Yet, the fluctuations in sales suggest that Gillanders may need to refine its strategies to stabilize revenue streams amidst changing market dynamics.
Profitability and Efficiency Metrics
Profitability remains a key concern for Gillanders Arbuthnot, particularly as the operating profit margin (OPM) stood at a stark -0.14%. The trend in operating profit over the last few quarters has been erratic, with losses recorded in multiple periods, including a significant dip to -21.47% in March 2023. This is troubling, especially when juxtaposed with the company’s historical performance. The net profit for the fiscal year ending March 2025 was ₹27 Cr, a recovery from a loss of ₹49 Cr the previous year, indicating some operational resilience. However, the return on equity (ROE) lingers at a modest 6.83%, which may not be compelling for investors seeking robust returns. The interest coverage ratio, reported at 2.93x, suggests that the company can cover its interest obligations comfortably, yet the overall profitability metrics indicate that there is much room for improvement in operational efficiency and cost management.
Balance Sheet Strength and Financial Ratios
Gillanders Arbuthnot’s balance sheet presents a mixed picture of financial health. The company has total borrowings of ₹147 Cr against reserves of ₹234 Cr, giving it a relatively comfortable debt-to-equity ratio of 0.51. This suggests that while the company is leveraging debt, it is doing so at a manageable level. Additionally, the current ratio of 0.96 indicates that the company is close to being able to meet its short-term obligations, though it falls slightly short of the ideal benchmark of 1.0. The book value per share stands at ₹114.88, which is encouraging, particularly when compared to the current market price of ₹108, indicating that the stock may be undervalued. However, the cash conversion cycle of 146 days is somewhat extended, which can strain liquidity. Investors should weigh this balance sheet resilience against the backdrop of fluctuating profitability and operational challenges.
Shareholding Pattern and Investor Confidence
The shareholding structure of Gillanders Arbuthnot reveals a strong promoter presence, with promoters holding 69.05% of the shares. This significant stake can instill confidence in minority investors, as it suggests that the management is heavily invested in the company’s success. However, foreign institutional investors (FIIs) have shown no interest, holding 0% of the shares, while domestic institutional investors (DIIs) account for a mere 0.31%. This lack of institutional backing could be a red flag, potentially signaling a lack of confidence in the company’s prospects among larger investors. The public float stands at 30.60%, with the number of shareholders increasing to over 10,000, reflecting a steady interest from retail investors. This engagement is crucial for liquidity but raises questions about whether the company’s fundamentals can support this growing interest amidst its operational challenges.
Outlook, Risks, and Final Insight
Looking ahead, Gillanders Arbuthnot faces a nuanced landscape filled with both opportunities and challenges. The company’s ability to stabilize revenues and improve profitability metrics will be critical. Key risks include ongoing volatility in operating margins and potential liquidity concerns stemming from an extended cash conversion cycle. Additionally, the lack of institutional investment might limit the stock’s upward momentum. Investors should also consider the broader economic environment, including commodity price fluctuations that could impact tea and coffee prices. Overall, while there are signs of recovery and potential for growth, prospective investors should approach this stock with caution, weighing the apparent strengths against the significant risks. A deeper focus on operational efficiency and strategic initiatives could ultimately dictate Gillanders Arbuthnot’s future performance in the competitive plantation industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Gillanders Arbuthnot & Company Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Goodricke Group Ltd | 363 Cr. | 168 | 295/162 | 149 | 0.00 % | 3.22 % | 2.86 % | 10.0 | |
| Diana Tea Company Ltd | 41.3 Cr. | 27.6 | 43.8/26.0 | 47.3 | 0.00 % | 1.40 % | 7.16 % | 5.00 | |
| Bengal Tea & Fabrics Ltd | 126 Cr. | 140 | 189/126 | 24.6 | 223 | 1.07 % | 5.22 % | 55.3 % | 10.0 |
| Bansisons Tea Industries Ltd | 8.62 Cr. | 13.6 | 13.6/5.60 | 9.42 | 0.00 % | 1.01 % | 1.01 % | 10.0 | |
| B&A Ltd | 119 Cr. | 385 | 689/371 | 12.8 | 528 | 0.00 % | 8.96 % | 6.02 % | 10.0 |
| Industry Average | 8,745.82 Cr | 393.16 | 69.61 | 265.00 | 0.43% | 7.88% | 16.74% | 7.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 124.81 | 143.56 | 103.24 | 77.42 | 87.68 | 105.42 | 101.43 | 68.75 | 84.85 | 126.75 | 127.64 | 103.94 | 88.37 |
| Expenses | 121.76 | 119.46 | 101.82 | 94.04 | 90.30 | 96.42 | 125.76 | 84.41 | 90.11 | 101.46 | 119.87 | 106.03 | 88.49 |
| Operating Profit | 3.05 | 24.10 | 1.42 | -16.62 | -2.62 | 9.00 | -24.33 | -15.66 | -5.26 | 25.29 | 7.77 | -2.09 | -0.12 |
| OPM % | 2.44% | 16.79% | 1.38% | -21.47% | -2.99% | 8.54% | -23.99% | -22.78% | -6.20% | 19.95% | 6.09% | -2.01% | -0.14% |
| Other Income | 12.60 | 3.91 | 6.07 | 7.67 | 4.59 | 1.86 | 8.25 | -1.07 | 1.74 | 3.53 | 13.23 | 3.99 | 0.49 |
| Interest | 5.24 | 4.39 | 3.99 | 4.42 | 3.98 | 3.51 | 3.94 | 2.86 | 3.46 | 2.85 | 2.95 | 3.10 | 3.24 |
| Depreciation | 2.95 | 3.09 | 3.01 | 2.91 | 3.03 | 3.15 | 2.86 | 2.72 | 2.67 | 2.78 | 2.80 | 2.61 | 2.65 |
| Profit before tax | 7.46 | 20.53 | 0.49 | -16.28 | -5.04 | 4.20 | -22.88 | -22.31 | -9.65 | 23.19 | 15.25 | -3.81 | -5.52 |
| Tax % | 8.58% | 11.89% | -51.02% | -33.54% | 4.37% | 13.33% | -2.32% | 10.49% | 1.76% | 7.37% | 14.56% | -153.54% | -1.27% |
| Net Profit | 6.81 | 18.09 | 0.74 | -10.81 | -5.26 | 3.64 | -22.35 | -24.65 | -9.82 | 21.47 | 13.03 | 2.04 | -5.46 |
| EPS in Rs | 3.19 | 8.48 | 0.35 | -5.07 | -2.46 | 1.71 | -10.47 | -11.55 | -4.60 | 10.06 | 6.11 | 0.96 | -2.56 |
Last Updated: August 20, 2025, 10:30 am
Below is a detailed analysis of the quarterly data for Gillanders Arbuthnot & Company Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 88.37 Cr.. The value appears to be declining and may need further review. It has decreased from 103.94 Cr. (Mar 2025) to 88.37 Cr., marking a decrease of 15.57 Cr..
- For Expenses, as of Jun 2025, the value is 88.49 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 106.03 Cr. (Mar 2025) to 88.49 Cr., marking a decrease of 17.54 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.12 Cr.. The value appears strong and on an upward trend. It has increased from -2.09 Cr. (Mar 2025) to -0.12 Cr., marking an increase of 1.97 Cr..
- For OPM %, as of Jun 2025, the value is -0.14%. The value appears strong and on an upward trend. It has increased from -2.01% (Mar 2025) to -0.14%, marking an increase of 1.87%.
- For Other Income, as of Jun 2025, the value is 0.49 Cr.. The value appears to be declining and may need further review. It has decreased from 3.99 Cr. (Mar 2025) to 0.49 Cr., marking a decrease of 3.50 Cr..
- For Interest, as of Jun 2025, the value is 3.24 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.10 Cr. (Mar 2025) to 3.24 Cr., marking an increase of 0.14 Cr..
- For Depreciation, as of Jun 2025, the value is 2.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.61 Cr. (Mar 2025) to 2.65 Cr., marking an increase of 0.04 Cr..
- For Profit before tax, as of Jun 2025, the value is -5.52 Cr.. The value appears to be declining and may need further review. It has decreased from -3.81 Cr. (Mar 2025) to -5.52 Cr., marking a decrease of 1.71 Cr..
- For Tax %, as of Jun 2025, the value is -1.27%. The value appears to be increasing, which may not be favorable. It has increased from -153.54% (Mar 2025) to -1.27%, marking an increase of 152.27%.
- For Net Profit, as of Jun 2025, the value is -5.46 Cr.. The value appears to be declining and may need further review. It has decreased from 2.04 Cr. (Mar 2025) to -5.46 Cr., marking a decrease of 7.50 Cr..
- For EPS in Rs, as of Jun 2025, the value is -2.56. The value appears to be declining and may need further review. It has decreased from 0.96 (Mar 2025) to -2.56, marking a decrease of 3.52.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:19 am
| Metric | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 355 | 863 | 817 | 681 | 665 | 751 | 660 | 431 | 406 | 449 | 363 | 443 | 447 |
| Expenses | 333 | 821 | 812 | 653 | 615 | 686 | 632 | 400 | 377 | 437 | 397 | 417 | 416 |
| Operating Profit | 22 | 42 | 5 | 28 | 50 | 65 | 28 | 31 | 30 | 12 | -34 | 26 | 31 |
| OPM % | 6% | 5% | 1% | 4% | 7% | 9% | 4% | 7% | 7% | 3% | -9% | 6% | 7% |
| Other Income | 11 | 9 | 12 | 30 | 21 | 12 | 26 | 7 | 17 | 30 | 14 | 22 | 21 |
| Interest | 10 | 42 | 51 | 54 | 50 | 50 | 48 | 37 | 23 | 18 | 14 | 12 | 12 |
| Depreciation | 9 | 21 | 19 | 22 | 24 | 20 | 20 | 16 | 12 | 12 | 12 | 11 | 11 |
| Profit before tax | 14 | -12 | -53 | -18 | -4 | 7 | -12 | -15 | 11 | 12 | -46 | 25 | 29 |
| Tax % | 21% | -27% | 4% | 4% | 112% | 95% | 22% | 2% | -42% | -22% | 6% | -7% | |
| Net Profit | 11 | -9 | -55 | -19 | -9 | 0 | -15 | -16 | 16 | 15 | -49 | 27 | 31 |
| EPS in Rs | 6.69 | -4.16 | -25.93 | -8.83 | -4.02 | 0.15 | -7.13 | -7.32 | 7.66 | 6.94 | -22.78 | 12.52 | 14.57 |
| Dividend Payout % | 25% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -511.11% | 65.45% | 52.63% | 100.00% | -6.67% | 200.00% | -6.25% | -426.67% | 155.10% |
| Change in YoY Net Profit Growth (%) | 0.00% | 576.57% | -12.82% | 47.37% | -106.67% | 206.67% | -206.25% | -420.42% | 581.77% |
Gillanders Arbuthnot & Company Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -8% |
| 3 Years: | 3% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 21% |
| 3 Years: | 0% |
| TTM: | 139% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 34% |
| 3 Years: | 21% |
| 1 Year: | 42% |
| Return on Equity | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -2% |
| 3 Years: | -4% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 4:45 am
Balance Sheet
Last Updated: December 4, 2025, 1:17 am
| Month | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 107 | 266 | 155 | 262 | 271 | 268 | 255 | 231 | 248 | 255 | 196 | 224 | 234 |
| Borrowings | 91 | 456 | 480 | 449 | 424 | 392 | 366 | 227 | 183 | 145 | 129 | 139 | 147 |
| Other Liabilities | 72 | 242 | 209 | 203 | 225 | 244 | 214 | 145 | 144 | 129 | 130 | 130 | 128 |
| Total Liabilities | 281 | 985 | 865 | 936 | 942 | 925 | 857 | 624 | 597 | 550 | 477 | 514 | 530 |
| Fixed Assets | 112 | 421 | 310 | 441 | 432 | 427 | 421 | 315 | 312 | 298 | 263 | 256 | 253 |
| CWIP | 10 | 11 | 4 | 9 | 17 | 14 | 15 | 14 | 12 | 11 | 9 | 13 | 16 |
| Investments | 13 | 28 | 28 | 29 | 34 | 29 | 17 | 8 | 3 | 0 | 0 | 0 | 0 |
| Other Assets | 145 | 525 | 522 | 457 | 460 | 454 | 404 | 287 | 271 | 241 | 205 | 245 | 260 |
| Total Assets | 281 | 985 | 865 | 936 | 942 | 925 | 857 | 624 | 597 | 550 | 477 | 514 | 530 |
Below is a detailed analysis of the balance sheet data for Gillanders Arbuthnot & Company Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Reserves, as of Sep 2025, the value is 234.00 Cr.. The value appears strong and on an upward trend. It has increased from 224.00 Cr. (Mar 2025) to 234.00 Cr., marking an increase of 10.00 Cr..
- For Borrowings, as of Sep 2025, the value is 147.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 139.00 Cr. (Mar 2025) to 147.00 Cr., marking an increase of 8.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 128.00 Cr.. The value appears to be improving (decreasing). It has decreased from 130.00 Cr. (Mar 2025) to 128.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 530.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 514.00 Cr. (Mar 2025) to 530.00 Cr., marking an increase of 16.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 253.00 Cr.. The value appears to be declining and may need further review. It has decreased from 256.00 Cr. (Mar 2025) to 253.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 3.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 260.00 Cr.. The value appears strong and on an upward trend. It has increased from 245.00 Cr. (Mar 2025) to 260.00 Cr., marking an increase of 15.00 Cr..
- For Total Assets, as of Sep 2025, the value is 530.00 Cr.. The value appears strong and on an upward trend. It has increased from 514.00 Cr. (Mar 2025) to 530.00 Cr., marking an increase of 16.00 Cr..
Notably, the Reserves (234.00 Cr.) exceed the Borrowings (147.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -69.00 | -414.00 | -475.00 | -421.00 | -374.00 | -327.00 | -338.00 | -196.00 | -153.00 | -133.00 | -163.00 | -113.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 26 | 56 | 57 | 54 | 53 | 47 | 45 | 54 | 36 | 21 | 29 | 51 |
| Inventory Days | 130 | 135 | 156 | 207 | 253 | 219 | 206 | 240 | 389 | 287 | 314 | 225 |
| Days Payable | 97 | 92 | 112 | 148 | 180 | 166 | 164 | 163 | 220 | 129 | 164 | 130 |
| Cash Conversion Cycle | 59 | 99 | 101 | 113 | 126 | 100 | 87 | 130 | 204 | 179 | 180 | 146 |
| Working Capital Days | 72 | -21 | 1 | -6 | -24 | -25 | -47 | -11 | 2 | -1 | -11 | -7 |
| ROCE % | 10% | -0% | 1% | 6% | 8% | 4% | 4% | 7% | 4% | -8% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 12.52 | -22.78 | 6.95 | 7.66 | -7.32 |
| Diluted EPS (Rs.) | 12.52 | -22.78 | 6.95 | 7.66 | -7.32 |
| Cash EPS (Rs.) | 17.61 | -17.27 | 12.55 | 13.49 | 0.19 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 114.88 | 101.89 | 129.69 | 126.44 | 118.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 114.88 | 101.89 | 129.69 | 126.44 | 118.37 |
| Revenue From Operations / Share (Rs.) | 207.65 | 170.22 | 210.39 | 190.42 | 201.83 |
| PBDIT / Share (Rs.) | 16.98 | -9.36 | 14.78 | 22.12 | 18.70 |
| PBIT / Share (Rs.) | 11.89 | -14.87 | 9.18 | 16.29 | 11.19 |
| PBT / Share (Rs.) | 11.70 | -21.56 | 5.71 | 5.38 | -7.15 |
| Net Profit / Share (Rs.) | 12.52 | -22.78 | 6.95 | 7.66 | -7.32 |
| NP After MI And SOA / Share (Rs.) | 12.52 | -22.78 | 6.95 | 7.66 | -7.32 |
| PBDIT Margin (%) | 8.17 | -5.50 | 7.02 | 11.61 | 9.26 |
| PBIT Margin (%) | 5.72 | -8.73 | 4.36 | 8.55 | 5.54 |
| PBT Margin (%) | 5.63 | -12.66 | 2.71 | 2.82 | -3.54 |
| Net Profit Margin (%) | 6.02 | -13.38 | 3.30 | 4.02 | -3.62 |
| NP After MI And SOA Margin (%) | 6.02 | -13.38 | 3.30 | 4.02 | -3.62 |
| Return on Networth / Equity (%) | 10.89 | -22.35 | 5.35 | 6.05 | -6.18 |
| Return on Capital Employeed (%) | 8.60 | -12.43 | 6.06 | 9.99 | 6.96 |
| Return On Assets (%) | 5.19 | -10.19 | 2.69 | 2.73 | -2.50 |
| Long Term Debt / Equity (X) | 0.05 | 0.08 | 0.09 | 0.21 | 0.30 |
| Total Debt / Equity (X) | 0.51 | 0.53 | 0.47 | 0.63 | 0.73 |
| Asset Turnover Ratio (%) | 0.89 | 0.70 | 0.78 | 0.64 | 0.56 |
| Current Ratio (X) | 0.96 | 0.85 | 1.01 | 1.03 | 0.99 |
| Quick Ratio (X) | 0.45 | 0.36 | 0.47 | 0.50 | 0.61 |
| Inventory Turnover Ratio (X) | 0.46 | 0.52 | 0.78 | 0.95 | 0.57 |
| Interest Coverage Ratio (X) | 2.93 | -1.40 | 1.75 | 2.03 | 1.08 |
| Interest Coverage Ratio (Post Tax) (X) | 2.20 | -2.41 | 1.23 | 1.70 | 0.63 |
| Enterprise Value (Cr.) | 343.60 | 282.86 | 273.58 | 318.10 | 271.78 |
| EV / Net Operating Revenue (X) | 0.77 | 0.77 | 0.60 | 0.78 | 0.63 |
| EV / EBITDA (X) | 9.48 | -14.15 | 8.67 | 6.74 | 6.81 |
| MarketCap / Net Operating Revenue (X) | 0.46 | 0.43 | 0.29 | 0.34 | 0.21 |
| Price / BV (X) | 0.83 | 0.71 | 0.47 | 0.51 | 0.36 |
| Price / Net Operating Revenue (X) | 0.46 | 0.43 | 0.29 | 0.34 | 0.21 |
| EarningsYield | 0.13 | -0.31 | 0.11 | 0.11 | -0.16 |
After reviewing the key financial ratios for Gillanders Arbuthnot & Company Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 12.52. This value is within the healthy range. It has increased from -22.78 (Mar 24) to 12.52, marking an increase of 35.30.
- For Diluted EPS (Rs.), as of Mar 25, the value is 12.52. This value is within the healthy range. It has increased from -22.78 (Mar 24) to 12.52, marking an increase of 35.30.
- For Cash EPS (Rs.), as of Mar 25, the value is 17.61. This value is within the healthy range. It has increased from -17.27 (Mar 24) to 17.61, marking an increase of 34.88.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 114.88. It has increased from 101.89 (Mar 24) to 114.88, marking an increase of 12.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 114.88. It has increased from 101.89 (Mar 24) to 114.88, marking an increase of 12.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 207.65. It has increased from 170.22 (Mar 24) to 207.65, marking an increase of 37.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 16.98. This value is within the healthy range. It has increased from -9.36 (Mar 24) to 16.98, marking an increase of 26.34.
- For PBIT / Share (Rs.), as of Mar 25, the value is 11.89. This value is within the healthy range. It has increased from -14.87 (Mar 24) to 11.89, marking an increase of 26.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 11.70. This value is within the healthy range. It has increased from -21.56 (Mar 24) to 11.70, marking an increase of 33.26.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 12.52. This value is within the healthy range. It has increased from -22.78 (Mar 24) to 12.52, marking an increase of 35.30.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 12.52. This value is within the healthy range. It has increased from -22.78 (Mar 24) to 12.52, marking an increase of 35.30.
- For PBDIT Margin (%), as of Mar 25, the value is 8.17. This value is below the healthy minimum of 10. It has increased from -5.50 (Mar 24) to 8.17, marking an increase of 13.67.
- For PBIT Margin (%), as of Mar 25, the value is 5.72. This value is below the healthy minimum of 10. It has increased from -8.73 (Mar 24) to 5.72, marking an increase of 14.45.
- For PBT Margin (%), as of Mar 25, the value is 5.63. This value is below the healthy minimum of 10. It has increased from -12.66 (Mar 24) to 5.63, marking an increase of 18.29.
- For Net Profit Margin (%), as of Mar 25, the value is 6.02. This value is within the healthy range. It has increased from -13.38 (Mar 24) to 6.02, marking an increase of 19.40.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.02. This value is below the healthy minimum of 8. It has increased from -13.38 (Mar 24) to 6.02, marking an increase of 19.40.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.89. This value is below the healthy minimum of 15. It has increased from -22.35 (Mar 24) to 10.89, marking an increase of 33.24.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.60. This value is below the healthy minimum of 10. It has increased from -12.43 (Mar 24) to 8.60, marking an increase of 21.03.
- For Return On Assets (%), as of Mar 25, the value is 5.19. This value is within the healthy range. It has increased from -10.19 (Mar 24) to 5.19, marking an increase of 15.38.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.08 (Mar 24) to 0.05, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.51. This value is within the healthy range. It has decreased from 0.53 (Mar 24) to 0.51, marking a decrease of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.89. It has increased from 0.70 (Mar 24) to 0.89, marking an increase of 0.19.
- For Current Ratio (X), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 1.5. It has increased from 0.85 (Mar 24) to 0.96, marking an increase of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.36 (Mar 24) to 0.45, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 4. It has decreased from 0.52 (Mar 24) to 0.46, marking a decrease of 0.06.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.93. This value is below the healthy minimum of 3. It has increased from -1.40 (Mar 24) to 2.93, marking an increase of 4.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 3. It has increased from -2.41 (Mar 24) to 2.20, marking an increase of 4.61.
- For Enterprise Value (Cr.), as of Mar 25, the value is 343.60. It has increased from 282.86 (Mar 24) to 343.60, marking an increase of 60.74.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.77.
- For EV / EBITDA (X), as of Mar 25, the value is 9.48. This value is within the healthy range. It has increased from -14.15 (Mar 24) to 9.48, marking an increase of 23.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.43 (Mar 24) to 0.46, marking an increase of 0.03.
- For Price / BV (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has increased from 0.71 (Mar 24) to 0.83, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.43 (Mar 24) to 0.46, marking an increase of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.13. This value is below the healthy minimum of 5. It has increased from -0.31 (Mar 24) to 0.13, marking an increase of 0.44.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gillanders Arbuthnot & Company Ltd:
- Net Profit Margin: 6.02%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.6% (Industry Average ROCE: 7.88%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.89% (Industry Average ROE: 16.74%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.2
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.45
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.1 (Industry average Stock P/E: 69.61)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.51
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.02%
Fundamental Analysis of Gillanders Arbuthnot & Company Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Plantations - Tea & Coffee | C-4, Gillander House, Netaji Subhas Road Kolkata West Bengal 700001 | gillander@gillandersarbuthnot.com http://www.gillandersarbuthnot.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arun Kumar Kothari | Chairman |
| Mr. Mahesh Sodhani | Managing Director |
| Mr. Manoj Sodhani | Executive Director & CEO |
| Mr. N Pachisia | Independent Director |
| Mrs. Prabhawati Devi Kothari | Non Executive Director |
| Mr. Arvind Baheti | Independent Director |
| Mr. Charudatta Raghvendra Prayag | Independent Director |
| Mr. Kothaneth Ashok | Independent Director |
Gillanders Arbuthnot & Company Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹81.10 |
| Previous Day | ₹83.10 |
FAQ
What is the intrinsic value of Gillanders Arbuthnot & Company Ltd?
Gillanders Arbuthnot & Company Ltd's intrinsic value (as of 09 December 2025) is 107.68 which is 4.54% higher the current market price of 103.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 221 Cr. market cap, FY2025-2026 high/low of 152/91.6, reserves of ₹234 Cr, and liabilities of 530 Cr.
What is the Market Cap of Gillanders Arbuthnot & Company Ltd?
The Market Cap of Gillanders Arbuthnot & Company Ltd is 221 Cr..
What is the current Stock Price of Gillanders Arbuthnot & Company Ltd as on 09 December 2025?
The current stock price of Gillanders Arbuthnot & Company Ltd as on 09 December 2025 is 103.
What is the High / Low of Gillanders Arbuthnot & Company Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gillanders Arbuthnot & Company Ltd stocks is 152/91.6.
What is the Stock P/E of Gillanders Arbuthnot & Company Ltd?
The Stock P/E of Gillanders Arbuthnot & Company Ltd is 16.1.
What is the Book Value of Gillanders Arbuthnot & Company Ltd?
The Book Value of Gillanders Arbuthnot & Company Ltd is 120.
What is the Dividend Yield of Gillanders Arbuthnot & Company Ltd?
The Dividend Yield of Gillanders Arbuthnot & Company Ltd is 0.00 %.
What is the ROCE of Gillanders Arbuthnot & Company Ltd?
The ROCE of Gillanders Arbuthnot & Company Ltd is 6.80 %.
What is the ROE of Gillanders Arbuthnot & Company Ltd?
The ROE of Gillanders Arbuthnot & Company Ltd is 6.83 %.
What is the Face Value of Gillanders Arbuthnot & Company Ltd?
The Face Value of Gillanders Arbuthnot & Company Ltd is 10.0.